Skip to main content

Kengreal

cangrelor
Used for Heart Attack

Kengreal (cangrelor) is an antiplatelet (blood thinner) medication that helps prevent blood clots. It's given as a continuous infusion through the veins to people in the hospital during a procedure that opens clogged blood vessels. It's an expensive medication, because it's available only as a brand name.

Reviewed by:Last reviewed on May 10, 2022
basics-icon

What is Kengreal (cangrelor)?

Drug facts

Common BrandsKengreal
Drug ClassAntiplatelet
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
faq-icon

Common questions about Kengreal (cangrelor)

Kengreal (cangrelor) is used to stop blood clots from forming. It's used in the hospital for adults undergoing percutaneous coronary intervention (PCI, a procedure to open clogged blood vessels) who aren't given certain other types of antiplatelet medications. It's also used off label for people who will undergo heart surgery and are required to stop taking their antiplatelet medication by mouth (e.g., clopidogrel (Plavix), prasugrel (Effient), Brilinta (ticagrelor)). Stopping the oral antiplatelet medication a couple days before surgery is important to give time for its long-lasting, blood-thinning effect to go away to prevent major bleeding at the surgical site. Since Kengreal (cangrelor) doesn't stay in the body for very long, it helps lower the risk for blood clots and its consequences (e.g., stroke) while they're waiting for surgery.

Kengreal (cangrelor) is an antiplatelet. Platelets are blood cells that form clots to help stop any bleeding. But clots can be dangerous if they form in your blood vessels since they can block bloodflow, which can lead to a heart attack and other complications. By preventing your platelets from clumping together in your blood, Kengreal (cangrelor) prevents blood clots from forming. This can help lower your risk for heart attack and clot formation in a stent during PCI.

Kengreal (cangrelor) is given as an injection through the veins (intravenous or IV). This is done by a trained healthcare provider who will make sure you get this medication at the correct dose and time. In general, the dose for PCI is 30 mcg/kg of body weight given as a single, quick injection into the veins to get your blood levels of Kengreal (cangrelor) high in a short amount of time (loading dose). Then, it's given as a 4 mcg/kg per minute continuous IV infusion for at least 2 hours or for the entire PCI procedure, whichever is longer. The dose for bridging to heart surgery is typically a lower-dose (0.75 mcg/kg per minute), continuous IV infusion until your heart surgery is complete and you can take antiplatelet medications by mouth again.

It depends on which oral antiplatelet medication your provider has instructed you to start taking. If your provider prescribed Brilinta (ticagrelor), you can start taking it any time during the Kengreal (cangrelor) infusion or right after the infusion. If your provider prescribed either clopidogrel (Plavix) or prasugrel (Effient), you can start taking it immediately after your Kengreal (cangrelor) infusion ends.

Since Kengreal (cangrelor) is a blood thinner, the most common side effect is bleeding. While you're in the hospital, your provider will monitor you closely for signs of bleeding during your Kengreal (cangrelor) infusion.

educational-icon

How to save using GoodRx

Compare Prices
1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
Select your free coupon
2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
Show coupon to your pharmacist
3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
Get free couponLearn more
dosage-icon

Kengreal (cangrelor) dosage

Typical dosage for Kengreal (cangrelor)

Get savings updates for Kengreal (cangrelor)

Receive price alerts, news, and other messages from GoodRx about Kengreal (cangrelor) and other healthcare topics and relevant savings offers.

By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men's health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.